

Invitation to Presentation of the CellaVision Report for the First Quarter 2026 on April 24, at 11:00 CEST

CellaVision AB (publ) will publish its report for the first quarter of 2026 on April 24, 2026, at 7:20 am CEST. The report will be available at www.cellavision.com.

In connection with the release of the report, analysts, investors, and media are hereby invited to a conference call and webcast at 11:00 am CEST, where Simon Østergaard, President & CEO, will present and comment on the report. The presentation will be in English.

To participate via webcast, please use the link below.

<https://cellavision.events.inderes.com/q1-report-2026>

To participate via conference call, please register at the link below. After registration, you will be provided with phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.

<https://events.inderes.com/cellavision/q1-report-2026/dial-in>

No pre-registration is required. Please dial in 5-10 minutes before the scheduled start time to facilitate a timely start.

Contact

Lisa Bodily Nordqvist
Investor Relations and Corporate Communications Manager
Phone: + 46 76 345 31 87
E-mail: lisa.bodilynordqvist@cellavision.com
www.cellavision.com

About Us

CellaVision is a global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. These analyses play a vital role in swift and accurate disease diagnoses, particularly in cases of infections and serious cancer diseases. The products replace manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in sample preparation, image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the parent company in Lund and by the company's 13 local market support organizations covering more than 40 countries. In 2025, sales were SEK 759 million and the company's growth target is 15% per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Mid Cap list. Read more at www.cellavision.com

Attachments

[Invitation to Presentation of the CellaVision Report for the First Quarter 2026 on April 24, at 11:00 CEST](#)